BRAF and melanoma: Given the revolution that targeted drugs constituted as inhibitor-based drugs against melanomas harbouring mutations in BRAF, MEK, and KIT [28,29], studies like the present one contribute to the identification of potential lines of work aimed at improving the medical attention of these patients.